267 related articles for article (PubMed ID: 23537059)
21. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
[TBL] [Abstract][Full Text] [Related]
22. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus.
Zampieri S; Alaibac M; Iaccarino L; Rondinone R; Ghirardello A; Sarzi-Puttini P; Peserico A; Doria A
Ann Rheum Dis; 2006 Apr; 65(4):545-8. PubMed ID: 16096331
[TBL] [Abstract][Full Text] [Related]
23. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications.
Chlebus E; Wolska H; Blaszczyk M; Jablonska S
J Am Acad Dermatol; 1998 Mar; 38(3):405-12. PubMed ID: 9520021
[TBL] [Abstract][Full Text] [Related]
24. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
25. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
26. The different faces of cutaneous lupus erythematosus.
Renner R; Sticherling M
G Ital Dermatol Venereol; 2009 Apr; 144(2):135-47. PubMed ID: 19357621
[TBL] [Abstract][Full Text] [Related]
27. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
DI Franco M; Paradiso M; Ceccarelli F; Scrivo R; Spinelli FR; Iannuccelli C; Valesini G
J Rheumatol; 2012 Jan; 39(1):41-5. PubMed ID: 22045840
[TBL] [Abstract][Full Text] [Related]
28. Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
[TBL] [Abstract][Full Text] [Related]
29. Nitrendipine-induced subacute cutaneous lupus erythematosus.
Marzano AV; Borghi A; Mercogliano M; Facchetti M; Caputo R
Eur J Dermatol; 2003; 13(2):213-6. PubMed ID: 12695145
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
31. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.
Figueredo Zamora E; Callen JP; Schadt CR
Lupus; 2021 Apr; 30(4):661-663. PubMed ID: 33349110
[TBL] [Abstract][Full Text] [Related]
33. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.
Almebayadh M; Regnier-Rosencher E; Carlotti A; Goulvestre C; Le Guern V; Mouthon L; Avril MF; Dupin N
Dermatology; 2013; 226(2):119-23. PubMed ID: 23548825
[TBL] [Abstract][Full Text] [Related]
34. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
35. [Cutaneous lupus induced by etanercept in rheumatoid arthritis].
Abourazzak FE; Guggenbuhl P; Perdriger A; Meadeb J; Gando-Cocley N; Chevrant-Breton J; Hajjaj-Hassouni N; Chalès G
Rev Med Interne; 2008 Sep; 29(9):744-7. PubMed ID: 18676065
[TBL] [Abstract][Full Text] [Related]
36. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab.
Kieu V; O'Brien T; Yap LM; Baker C; Foley P; Mason G; Prince HM; McCormack C
Australas J Dermatol; 2009 Aug; 50(3):202-6. PubMed ID: 19659984
[TBL] [Abstract][Full Text] [Related]
37. Subacute cutaneous lupus erythematosus on the lines of Blaschko.
Röckmann H; Feller G; Schadendorf D; Goerdt S
Eur J Dermatol; 2006; 16(3):302-6. PubMed ID: 16709500
[TBL] [Abstract][Full Text] [Related]
38. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
[TBL] [Abstract][Full Text] [Related]
39. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
40. TNF inhibitors - new and old agents for rheumatoid arthritis.
Simsek I
Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
